Therapy resistance mechanisms in hematological malignancies

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• Hematologic malignancies serve as crucial models for cancer research and therapy development.
• Despite advances, treatment resistance and relapse remain significant challenges, leading to high mortality.
• Understanding resistance mechanisms is critical for improving patient outcomes in leukemia, lymphoma, and myeloma.

Purpose of the Study:

• To review the mechanisms underlying treatment resistance in hematologic malignancies.
• To highlight the role of cellular heterogeneity, plasticity, and adaptive processes in therapy resistance.
• To discuss how recent technological advancements can elucidate these resistance mechanisms.

Main Methods:

• Review of current literature on hematologic malignancies and treatment resistance.
• Discussion of cellular heterogeneity, plasticity, and adaptive genetic/epigenetic processes.
• Exploration of novel multi-omics technologies, single-cell resolution, biocomputational approaches, and AI.

Main Results:

• Cellular heterogeneity and plasticity, along with adaptive genetic and epigenetic changes, contribute to treatment resistance.
• Therapy-resistant cells in minimal residual disease (MRD) possess poorly understood molecular characteristics.
• Resistance mechanisms may be conserved across different hematologic cancer types.

Conclusions:

• Understanding the mechanisms of treatment resistance is essential for developing more effective therapies for hematologic malignancies.
• Advanced technologies like single-cell multi-omics and AI are vital for dissecting resistance at an unprecedented resolution.
• Further research into resistance mechanisms promises to improve outcomes for patients with relapsed and refractory hematologic cancers.